Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas
- OPACC
- Jun 9, 2022
- 1 min read
The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas.
Comentarios